AbbVie Inc. ABBV34.SA Stock
AbbVie Inc. Price Chart
AbbVie Inc. ABBV34.SA Financial and Trading Overview
AbbVie Inc. stock price | 51.75 BRL |
Previous Close | 41 BRL |
Open | 0 BRL |
Bid | 40.71 BRL x 0 |
Ask | 41.36 BRL x 0 |
Day's Range | 0 - 0 BRL |
52 Week Range | 0 - 56.1 BRL |
Volume | 0 BRL |
Avg. Volume | 3.26K BRL |
Market Cap | 1.17T BRL |
Beta (5Y Monthly) | 0.554225 |
PE Ratio (TTM) | 31.782948 |
EPS (TTM) | 0.86 BRL |
Forward Dividend & Yield | 1.85 (4.50%) |
Ex-Dividend Date | April 13, 2023 |
1y Target Est | N/A |
ABBV34.SA Valuation Measures
Enterprise Value | 128.1B BRL |
Trailing P/E | 31.782948 |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 20.603403 |
Price/Book (mrq) | 5.448505 |
Enterprise Value/Revenue | 2.258 |
Enterprise Value/EBITDA | 4.339 |
Trading Information
AbbVie Inc. Stock Price History
Beta (5Y Monthly) | 0.554225 |
52-Week Change | -7.80% |
S&P500 52-Week Change | 20.43% |
52 Week High | 56.1 BRL |
52 Week Low | 0 BRL |
50-Day Moving Average | 46.16 BRL |
200-Day Moving Average | 48.83 BRL |
ABBV34.SA Share Statistics
Avg. Volume (3 month) | 3.26K BRL |
Avg. Daily Volume (10-Days) | 7.71K BRL |
Shares Outstanding | 28.23B |
Float | 1.76B |
Short Ratio | N/A |
% Held by Insiders | 0% |
% Held by Institutions | 0.0040% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 5.78 |
Trailing Annual Dividend Yield | 14.09% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 1.0232 |
Last Split Factor | 16:1 |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 13.36% |
Operating Margin (ttm) | 36.97% |
Gross Margin | 70.95% |
EBITDA Margin | 52.03% |
Management Effectiveness
Return on Assets (ttm) | 9.44% |
Return on Equity (ttm) | 51.27% |
Income Statement
Revenue (ttm) | 56.74B BRL |
Revenue Per Share (ttm) | 32.04 BRL |
Quarterly Revenue Growth (yoy) | -9.70% |
Gross Profit (ttm) | 41.53B BRL |
EBITDA | 29.52B BRL |
Net Income Avi to Common (ttm) | 7.54B BRL |
Diluted EPS (ttm) | 1.29 |
Quarterly Earnings Growth (yoy) | -94.69% |
Balance Sheet
Total Cash (mrq) | 6.72B BRL |
Total Cash Per Share (mrq) | 3.81 BRL |
Total Debt (mrq) | 62.46B BRL |
Total Debt/Equity (mrq) | 469.53 BRL |
Current Ratio (mrq) | 0.96 |
Book Value Per Share (mrq) | 7.525 |
Cash Flow Statement
Operating Cash Flow (ttm) | 24.23B BRL |
Levered Free Cash Flow (ttm) | 21.6B BRL |
Profile of AbbVie Inc.
Country | Brazil |
State | IL |
City | North Chicago |
Address | 1 North Waukegan Road |
ZIP | 60064-6400 |
Phone | 847 932 7900 |
Website | https://www.abbvie.com |
Industry | Drug Manufacturers-General |
Sector(s) | Healthcare |
Full Time Employees | 50000 |
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition, the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis, a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech, Inc.; and Genentech, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Q&A For AbbVie Inc. Stock
What is a current ABBV34.SA stock price?
AbbVie Inc. ABBV34.SA stock price today per share is 51.75 BRL.
How to purchase AbbVie Inc. stock?
You can buy ABBV34.SA shares on the São Paulo exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for AbbVie Inc.?
The stock symbol or ticker of AbbVie Inc. is ABBV34.SA.
Which industry does the AbbVie Inc. company belong to?
The AbbVie Inc. industry is Drug Manufacturers-General.
How many shares does AbbVie Inc. have in circulation?
The max supply of AbbVie Inc. shares is 28.33B.
What is AbbVie Inc. Price to Earnings Ratio (PE Ratio)?
AbbVie Inc. PE Ratio is 60.17442000 now.
What was AbbVie Inc. earnings per share over the trailing 12 months (TTM)?
AbbVie Inc. EPS is 0.86 BRL over the trailing 12 months.
Which sector does the AbbVie Inc. company belong to?
The AbbVie Inc. sector is Healthcare.